Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib plus pegylated interferon alfa-2b frontline phase II study in newly diagnosed chronic-phase CML
2012-003389-42Phase 2Active
- Sponsor
- CHU de Poitiers
- Start
- May 2013
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of dasatinib and peginterferon alfa-2b in chronic myelogenous leukemia (CML), sponsored by CHU de Poitiers. Primary endpoint: Cumulative molecular response 4.5 rate at 12 months. Started May 2013; status: active.
02
Drugs
dasatinibpeginterferon alfa-2b
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on 2012-003389-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-003389-42.